The mosquitoes developed and raised here at the laboratories of Oxitec, a British biotech company based near Didcot, have already infiltrated wild populations in Brazil, Malaysia and the Cayman Islands. The company hopes that it will reduce populations of disease-carrying mosquitoes by 80%. [Oxitec] is primarily focused on ... the Aedes aegypti mosquito, which carries [dengue fever]. The main weapons against A aegypti, pesticides and education, have had little success in preventing its spread. Oxitec's chief scientific officer ... came up with an alternative using genetic modification. He produced mosquitoes that were engineered to need an antibiotic, tetracycline, to develop beyond larval stage. Critics of Oxitec say that the company is rushing to commercialise its products to provide a return on investment, massaging research while leaving key questions unanswered. Earlier this year, scientists at the Max Planck Institute for Evolutionary Biology in Germany examined information regarding the release of modified insects into the environment in Malaysia and Grand Cayman, which were carried out by Oxitec. The scientists' findings suggest that there are deficits in the scientific quality of regulatory documents and a general absence of accurate experimental descriptions available before releases start". Oxitec is now producing mosquitoes in Brazil. It recently reported that it reduced the number of Aedes mosquitoes by 85%, compared with an area where the company's mosquitoes weren't released.